2 / 8
Volume 8
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
Euro Biotechnology 2018
October 11-12, 2018
conference
series
.com
October 11-12, 2018 | Moscow, Russia
21
st
European
Biotechnology Congress
Page 10
Vladimir P Torchilin, J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C5-099
Next step in drug delivery: Getting inside cells and to individual organelles
T
here are already some means to deliver drugs inside cells bypassing the lysosomal degradation. Thus, coupling of cell-
penetrating peptides (CPP) to various molecules, including peptides and proteins, or even to nanoparticles, such as
liposomes, dramatically facilitates their intracellular delivery. Similar effect could be achieved using phage coat fusion proteins
purified from the phages selected for their specificity towards certain target cells as was shownwith liposome-loaded anticancer
drugs. The combination of targeted delivery of drug-loaded nanopreparations to target cells and their subsequent delivery
inside cells might still further improve the efficiency of therapy. Intracellular drug delivery with subsequent organelle targeting
opens new opportunities in overcoming problems associated with multiple pathologies including lysosomal storage diseases
and multidrug resistance (MDR) tumors. Delivery of deficient enzymes for the treatment of lysosomal diseases evidently
requires specific targeting of lysosomes, while facilitating apoptotic cell death in MDR tumor would require targeting of
mitochondria or lysosomes. Thus, next generation drug delivery systems should be able to target individual organelles inside
cells. Clearly, this challenge will require some novel approaches in engineering multifunctional nanomedicines, capable of
accumulating in the target tissue, penetrating inside cells, bypassing lysosomes, and bringing pharmaceuticals to individual
organelles. Examples of specific targeting of pharmaceutical nanocarriers loaded with pharmaceutical agents to lysosomes and
mitochondria in cells illustrate the benefits of this new approach.
Biography
Vladimir P Torchilin PhD DSc, is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology
and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive
pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews
and book chapters, wrote and edited 12 books, and hold more than 40 patents. Google Scholar shows more than 55,000 citations of his papers with H-index
of 105. He is Editor-in-Chief of
Current Drug Discovery Technologies, Drug Delivery,
and
OpenNano,
Co-Editor
of Current Pharmaceutical Biotechnology
and on the Editorial Boards of many other journals. He received more than $30M from the governmental and industrial sources in research funding. He
has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of
2000-2010.
v.torchilin@neu.eduVladimir P Torchilin
Northeastern University, USA